
- July/August 2013
- Volume 4
- Issue 4
HCV and OBI Co-Infections May Increase Poor Outcomes
The results of a new study, published online on June 10, 2013, in the Journal of Hepatology, have found that chronic hepatitis C patients who are also infected with occult hepatitis B have a higher risk of progressing toward cirrhosis and of developing hepatocellular carcinoma.
Researchers of the observational study tested 326 chronic hepatitis C patients for occult hepatitis B virus infections (OBIs) through the analysis of liver biopsy DNA extracts from 1991 to 2000. Almost 40% of patients tested OBI positive and 94 of the original 326 were followed up for at least 5 years and for a maximum of 19 years. During the follow-up period, 79 patients received anti-hepatitis C virus treatments and 26 achieved a sustained virological response.
Approximately 35% of OBI-positive patients developed hepatocellular carcinoma, compared with just 9% of patients without OBI. Among patients who did not develop hepatocellular carcinoma, 33% of those with OBI developed advanced forms of cirrhosis, while only 13% of those infected with hepatitis C alone suffered cirrhosis. Of the 18 patients who died from liver-related causes during the follow-up period, 12 were OBI positive.
The researchers conclude that individuals infected with both hepatitis C and occult hepatitis B may have increased rated of cirrhosis and hepatocellular carcinoma and decreased rates of survival.
Articles in this issue
over 12 years ago
September-October 2013 Meetingsover 12 years ago
Growth Hormone Therapy: A Specialty Pharmacy Overviewover 12 years ago
Many Antibody-Positive Patients Are Never HCV RNA Testedover 12 years ago
RSV Infections in Infancy Linked to Wheezing in Childhoodover 12 years ago
Triple Therapy May Cause More Adverse Reactions in HCV Patientsover 12 years ago
Adding a Specialty Pharmacy to Your Retail Brandover 12 years ago
How Smartphones Will Transform Your Patient Relationshipsover 12 years ago
Who Really Knows Best?over 12 years ago
Distribution Networks: Why Limit Them?Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

















































































































































































































